$6.070
+0.180 (+2.97%)Zum Schluss
TRIB-News
TRIB-Events
Trinity Biotech Trading Halted Due to Volatility
Trinity Biotech trading halted, volatility trading pause
Trinity Biotech Trading Halted Due to Volatility
Trinity Biotech trading halted, volatility trading pause
Trinity Biotech Adjusts ADS Ratio to 1:600
Trinity Biotech announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing 20 Class A ordinary shares to one ADS representing 600 Class A ordinary shares. For Trinity Biotech ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to enable the company to regain compliance with the $1.00 Nasdaq minimum bid price requirement, and facilitate investment from a broader pool of potential investors, who may have previously been unable to invest due to the ADSs trading below a price of $5.00.
Trinity Biotech Signs Strategic Collaboration Agreement with Latch Medical
Trinity Biotech announced a strategic collaboration agreement with Latch Medical. The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision therapeutic solutions for diabetes, obesity and other metabolic conditions. The companies will explore how real-time metabolic data generated by CGM+ can be used to help guide and optimize therapeutic delivery, creating the potential for more personalized and responsive treatment approaches. As part of the collaboration, Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted strategic investment from established participants in the global drug delivery industry. Trinity Biotech's planned investment reflects its belief in the potential importance of precision intradermal delivery technologies within next-generation metabolic health solutions.
Trinity Biotech Officially Terminates Equity Purchase Agreement with Yorkville
Trinity Biotech announced that it has formally provided notice of termination to YA II PN, an affiliate of financing partner Yorkville Advisors Global, in respect of its standby equity purchase agreement, or SEPA, for an equity line of credit facility. The company has determined that it does not intend to make any further use of the SEPA. Accordingly, termination of the equity line of credit facility reflects the company's current financing strategy.
Ähnliche Artikel
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.